Lymphedema alters lipolytic, lipogenic, immune and angiogenic properties of adipose tissue: a hypothesis-generating study in breast cancer survivors.
Journal
Scientific reports
ISSN: 2045-2322
Titre abrégé: Sci Rep
Pays: England
ID NLM: 101563288
Informations de publication
Date de publication:
14 04 2021
14 04 2021
Historique:
received:
21
05
2020
accepted:
30
03
2021
entrez:
15
4
2021
pubmed:
16
4
2021
medline:
11
11
2021
Statut:
epublish
Résumé
Later stages of secondary lymphedema are associated with the massive deposition of adipose tissue (AT). The factors driving lymphedema-associated AT (LAT) expansion in humans remain rather elusive. We hypothesized that LAT expansion could be based on alterations of metabolic, adipogenic, immune and/or angiogenic qualities of AT. AT samples were acquired from upper limbs of 11 women with unilateral breast cancer-related lymphedema and 11 healthy women without lymphedema. Additional control group of 11 female breast cancer survivors without lymphedema was used to assess systemic effects of lymphedema. AT was analysed for adipocyte size, lipolysis, angiogenesis, secretion of cytokines, immune and stem cell content and mRNA gene expression. Further, adipose precursors were isolated and tested for their proliferative and adipogenic capacity. The effect of undrained LAT- derived fluid on adipogenesis was also examined. Lymphedema did not have apparent systemic effect on metabolism and cytokine levels, but it was linked with higher lymphocyte numbers and altered levels of several miRNAs in blood. LAT showed higher basal lipolysis, (lymph)angiogenic capacity and secretion of inflammatory cytokines when compared to healthy AT. LAT contained more activated CD4+ T lymphocytes than healthy AT. mRNA levels of (lymph)angiogenic markers were deregulated in LAT and correlated with markers of lipolysis. In vitro, adipose cells derived from LAT did not differ in their proliferative, adipogenic, lipogenic and lipolytic potential from cells derived from healthy AT. Nevertheless, exposition of preadipocytes to LAT-derived fluid improved their adipogenic conversion when compared with the effect of serum. This study presents results of first complex analysis of LAT from upper limb of breast cancer survivors. Identified LAT alterations indicate a possible link between (lymph)angiogenesis and lipolysis. In addition, our in vitro results imply that AT expansion in lymphedema could be driven partially by exposition of adipose precursors to undrained LAT-derived fluid.
Identifiants
pubmed: 33854130
doi: 10.1038/s41598-021-87494-3
pii: 10.1038/s41598-021-87494-3
pmc: PMC8046998
doi:
Substances chimiques
Cytokines
0
Types de publication
Comparative Study
Journal Article
Research Support, Non-U.S. Gov't
Langues
eng
Sous-ensembles de citation
IM
Pagination
8171Références
Obesity (Silver Spring). 2017 Jan;25(1):122-131
pubmed: 27883275
Metabolism. 2013 Mar;62(3):337-40
pubmed: 22999012
Plast Reconstr Surg. 2012 Apr;129(4):825-834
pubmed: 22456354
Proc Natl Acad Sci U S A. 2018 Feb 6;115(6):1298-1303
pubmed: 29358379
Proc Natl Acad Sci U S A. 2001 Oct 23;98(22):12677-82
pubmed: 11592985
Int J Obes. 1988;12(4):321-33
pubmed: 3198310
Methods Mol Biol. 2020;2104:337-360
pubmed: 31953825
Nature. 2017 Feb 23;542(7642):450-455
pubmed: 28199304
Methods Enzymol. 2014;537:75-91
pubmed: 24480342
J Invest Dermatol. 2016 Mar;136(3):706-714
pubmed: 27015456
Nat Genet. 2005 Oct;37(10):1072-81
pubmed: 16170315
Nature. 2017 Feb 2;542(7639):49-54
pubmed: 28024299
J Clin Endocrinol Metab. 2012 Oct;97(10):E1880-9
pubmed: 22851489
Endocr Rev. 2019 Feb 1;40(1):137-152
pubmed: 30307551
Am J Physiol Endocrinol Metab. 2011 Oct;301(4):E659-67
pubmed: 21750269
Cell Metab. 2012 Mar 7;15(3):279-91
pubmed: 22405066
Thyroid. 2011 Jun;21(6):663-74
pubmed: 21510802
Lymphat Res Biol. 2009;7(1):3-10
pubmed: 19231988
Adv Exp Med Biol. 2017;960:489-509
pubmed: 28585213
Inflamm Bowel Dis. 2016 Jun;22(6):1483-95
pubmed: 27167572
Biochim Biophys Acta Mol Cell Biol Lipids. 2020 Feb;1865(2):158576
pubmed: 31740387
Arterioscler Thromb Vasc Biol. 2006 Sep;26(9):1936-47
pubmed: 16778118
Nat Methods. 2012 Jun 28;9(7):676-82
pubmed: 22743772
J Biol Chem. 2006 Dec 8;281(49):38022-37
pubmed: 17032652
Cell Metab. 2018 Jul 03;28(1):45-54.e3
pubmed: 29861390
PLoS One. 2012;7(11):e49940
pubmed: 23185491
PLoS One. 2013 Dec 03;8(12):e82086
pubmed: 24312631
Clin Dermatol. 2014 Sep-Oct;32(5):685-91
pubmed: 25160111
Diabetologia. 2007 Jan;50(1):151-7
pubmed: 17096115
Diabetes. 2011 May;60(5):1458-66
pubmed: 21464445
J Clin Endocrinol Metab. 2020 Dec 1;105(12):
pubmed: 32902644
Front Immunol. 2019 Jan 29;10:76
pubmed: 30761143
Diabetes. 2013 Jun;62(6):1990-5
pubmed: 23378611
Adipocyte. 2018;7(2):96-105
pubmed: 29411671
Diabetes. 2010 Oct;59(10):2513-21
pubmed: 20530742
Cell Rep. 2013 Oct 31;5(2):482-92
pubmed: 24139798
Plast Reconstr Surg. 2013 Sep;132(3):580-589
pubmed: 23985633
Biol Trace Elem Res. 2020 Jan;193(1):81-88
pubmed: 30929134
Diabetes. 2013 Jun;62(6):1970-80
pubmed: 23378608
Br J Dermatol. 2017 Jul;177(1):158-167
pubmed: 28000916
Int J Mol Sci. 2017 Jan 17;18(1):
pubmed: 28106728
JAMA Oncol. 2019 Aug 15;:
pubmed: 31415063
Cell Tissue Res. 2020 Mar;379(3):511-520
pubmed: 31776824
J Clin Invest. 2013 Mar;123(3):1057-67
pubmed: 23426184
FEBS Lett. 2005 Jul 4;579(17):3797-801
pubmed: 15978586
JCI Insight. 2016 Feb 1;1(2):
pubmed: 26973883
Neoplasia. 2010 Apr;12(4):336-45
pubmed: 20360944
Biomed Opt Express. 2012 Jun 1;3(6):1256-65
pubmed: 22741072
Adipocyte. 2019 Dec;8(1):98-104
pubmed: 30848691
Front Immunol. 2013 Dec 16;4:424
pubmed: 24379811
Plast Reconstr Surg. 2012 Apr;129(4):838-847
pubmed: 22456356
J Clin Endocrinol Metab. 2003 Jul;88(7):3005-10
pubmed: 12843134
Microvasc Res. 2006 Nov;72(3):161-71
pubmed: 16876204
Circulation. 2009 Jan 20;119(2):281-9
pubmed: 19118255
Ann Anat. 2018 Sep;219:25-34
pubmed: 29842991
Plast Reconstr Surg. 2014 Jul;134(1):154e-160e
pubmed: 25028830
Genome Biol. 2006;7(10):R100
pubmed: 17076895